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Table 1\* p \<0.05 compared to controlGroupControl (n = 416 \[81.4%\])High ferritin (n = 58 \[11.4%\])High IL-18 (n = 54 \[10.6%\])SOFA score8.0 \[6.0 - 10.0\]9.0 \[8.0 - 12.0\]\*11.0 \[8.5 - 13.0\]\*Ventilator-free days15.0 \[0.0 - 22.0\]0.0 \[0.0 - 14.5\]\*7.5 \[0.0 - 21.0\]Mortality at 28 days21%38%\*35%\*Mortality at 12 months32%52%\*44%

Background
==========

Haemophagocytic Lymphohistiocytosis (HLH) is a rare hyperinflammatory condition. Ferritin and IL- 18 are elevated in cases of HLH, however their role in the pathogenesis of HLH is not understood. Plasma ferritin and IL-18 are recognised biomarkers for HLH. In patients with sepsis, an HLH-like syndrome (HLH-LS) has been reported (1). However, it is unknown if a similar HLH-like syndrome co- exists in patients with ARDS, and if it modifies outcomes in patients with ARDS.

Hypothesis
==========

We hypothesised that an HLH-LS occurs in patients with ARDS, and that its presence is associated with increased mortality.

Methods
=======

A post-hoc analysis of the HARP-2 clinical trial was undertaken. HARP-2 was a randomised, controlled clinical trial evaluating simvastatin in 540 patients with ARDS. Baseline plasma samples obtained were analysed for ferritin and total IL-18 using an enzyme-linked immunosorbent assay. Ferritin \>4000 ng/μL or a total IL-18\>2500 pg/μL have been reported to have a high sensitivity and specificity for the diagnosis of HLH-LS. Patients with high ferritin or high IL-18 values were compared to a control group with normal ferritin and IL-18 values.

Results
=======

511 patients where baseline samples were available were included. High baseline ferritin was present in 58 (11.4%) patients. These patients had a higher baseline SOFA score, fewer ventilator free days (VFDs) and higher 28-day and 12-month mortality. High baseline IL-18 was identified in 54 (10.6%) patients. These patients had a higher baseline SOFA score and higher 28-day mortality. Although these patients also had fewer VFDs and higher 12-month mortality, these findings were not statistically significant ([Table 1](#t01){ref-type="table"}).

Conclusion
==========

This post-hoc analysis demonstrates that an HLH-LS, identified by high ferritin or high IL-18, occurs in patients with ARDS. Furthermore, the presence of an HLH-LS with ARDS is associated with worse clinical outcomes. Identification of this co-existing HLH-LS might offer an opportunity to improve outcomes for this group of patients with ARDS.
